Evidence map›Paper›PMID 34537918›Full record

ArticleGenes & genomics2021

HIST1H2BN induced cell proliferation and EMT phenotype in prostate cancer via NF-κB signal pathway.

Juan Zhang, Yuhan Chang, Haiyan Xia, Luwei Xu, Xiaowei Wei

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Juan ZhangDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Yuhan ChangDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Haiyan Xia *Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. haiyxia@njmu.edu.cn.
Luwei Xu *Department of Urinary surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. xuluwei1980@126.com.
Xiaowei Wei *Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. gswxw@njmu.edu.cn.ORCID 0000-0002-3802-7845
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe potential role of HIST1H2BN in prostate cancer remains unclear.

objectiveTo evaluate the carcinogenic role of HIST1H2BN in prostate cancer.

methodsThe expression of HIST1H2BN in prostate cancer was analyzed using TCGA database and clinical samples. The roles and mechanisms of HIST1H2BN were investigated in DU145 and PC3 cells.

resultsHIST1H2BN was significantly upregulated in prostate cancer. HIST1H2BN knockdown inhibited cell proliferation, migration and EMT phenotype in prostate cancer cells. Downregulating HIST1H2BN diminished the expression and binding activity of NF-κB p65, then influenced the expression of MMP2 and MMP9.

conclusionThis is the first study to elaborate a HIST1H2BN-NF-κB-EMT regulatory axis in oncogenesis, indicating that HIST1H2BN might be potential therapeutic target for prostate cancer.

Indexed as

PhenotypeSignal TransductionCell Line, TumorCell MovementCell ProliferationDown-RegulationEpithelial-Mesenchymal TransitionHumansMaleNF-kappa BOrganic Cation Transporter 3Organic Cation Transport ProteinsProstatic NeoplasmsTranscription Factor RelAUp-RegulationNF-kappa BOrganic Cation Transporter 3Organic Cation Transport ProteinsRELA protein, humanTranscription Factor RelAEMTHIST1H2BNNF-κBProstate cancer

Identifiers

PMID34537918
OpenAlexW3201014616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.